Precision engineering designed phospholipid-tagged pamidronate complex functionalized SNEDDS for the treatment of postmenopausal osteoporosis

• Published in: Drug delivery and translational research Vol. 13; no. 3; pp. 883 - 913
• Main Authors: Solanki, Pavitra, Ansari, Mohd. Danish, Alam, Mohd. Iqbal, Aqil, Mohd, Ahmad, Farhan J., Sultana, Yasmin
• Format: Journal Article
• Language: English
• Published: New York Springer US 01.03.2023
• Subjects: Administration, Oral; Biological Availability; Biomedical and Life Sciences; Biomedicine; Drug Delivery Systems - methods; Emulsions; Female; Humans; Nanoparticles; Original Article; Osteoporosis, Postmenopausal - drug therapy; Pamidronate; Particle Size; Pharmaceutical Sciences/Technology; Phospholipids; Solubility; Pamidronate; Oral drug delivery; SNEDDS; Phospholipon 90G; Postmenopausal osteoporosis; Quality by design
• ISSN: 2190-393X; 2190-3948
• DOI: 10.1007/s13346-022-01259-7

Disodium pamidronate, a second-generation bisphosphonate is a potent drug for the treatment of osteoporosis, which has been very well established by previous literature. It has very low oral permeability, leading to its low oral bioavailability, which restrict this drug to being administered orally. Therefore, the present research work includes the development of an orally effective nanoformulation of pamidronate. In this work, disodium pamidronate was complexed with phospholipon 90G for the enhancement of permeability and to investigate the phospholipon 90G–tagged pamidronate complex–loaded SNEDDS for oral delivery with promises of enhanced bioavailability and anti-osteoporotic activity. The rational design and optimization was employed using Central Composite Design (Design Expert ® 12, software) to optimize nanoformulation parameters. In this work, a commercially potential self nano-emulsifying drug delivery system (SNEDDS) has been developed and evaluated for improved oral bioavailability and better clinical acceptance. The hot micro-emulsification and ultracentrifugation method with vortex mixing was utilized for effective tagging of phospholipon 90G with pamidronate and then loading into the SNEDDS nanocarrier. The optimized Pam-PLc SNEDDS formulation was characterized for particle size, PDI, and zeta potential and found to be 56.38 ± 1.37 nm, 0.218 ± 0.113, and 22.41 ± 1.14 respectively. Also, a 37.9% improved bioavailability of pamidronate compared to marketed tablet was observed. Similarly, in vivo pharmacokinetic studies suggest a 31.77% increased bone density and significant enhanced bone biomarkers compared to marketed tablets. The developed formulation is safe and effectively overcomes anti-osteoporosis promises with improved therapeutic potential. This work provides very significant achievements in postmenopausal osteoporosis treatment and may lead to possible use of nanotherapeutic-driven emerging biodegradable carriers-based drug delivery. Graphical Abstract